08 December 2000
Consequences of Labetalol Administration on Myocardial beta Adrenergic Receptors in the Brain Dead Pig
C Seguin, Y Devaux, N Aubert, E M Siaghy, F Zannad, P M MertesAnn Transplant 2000; 5(4): 54-60 :: ID: 497559
Abstract
Objectives: Cardiac dysfunction following brain death is associated with highly increased myocardial norepinephrine, lactate and adenosine concentrations. Administration of labetalol, a mixed a-, 13-adrenergic receptor antagonist, attenuates metabolic disturbances and improves myocardial function. The purpose of this study was to investigate p-adrenergic receptor (f3AR)density and affinity in the presence or absence of labetalol administration, as a possible mechanism of the protective effects of this drug. Methods: Experimental animals were divided into three groups: sham-operated, brain-dead pigs, and brain-dead pigs treated with labetalol (10 mg/kg). The maximum number of binding sites (Bmax) and the dissociation constant (Kd) of pAR were determined with(-) [125^I]cyanopindololon myocardial samples harvested 3 hours after brain death. Results: Left ventricular pAR density and affinity were identical in brain-dead and sham-operated animals. Labetalol-treated pigs exhibited a significant decrease of Bmax and an increase of Kdas compared with brain-dead pigs. Bmax decrease was due to the persistence of labetalol in the membrane preparations. Increased Kd was too low to be biologically significant. Therefore, pAR number and affinity can be considered as unchanged after adrenergic blockade with labetalol. Conclusions:The protective mechanism of labetalol on brain death-induced myocardial dysfunction cannot be explained by changes in pAR density and affinity but is probably related to a preservation of the oxygen consumption/oxygen delivery balance during the autonomic storm.
Keywords: Brain Death, beta-adrenergic receptor, adrenergic receptors antagonists, radioligand binding
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






